Searchable abstracts of presentations at key conferences in endocrinology

ea0049oc8.4 | Neuroendocrinology | ECE2017

Cerebrovascular stroke incidence in GH-treated adults: experience from KIMS (Pfizer International Metabolic Database)

Camacho-Hubner Cecilia , Cara Jose , Mattsson Anders

Background and aim: Patients with GH deficiency (GHD) have increased risk of cerebrovascular events. The aim of this study was to evaluate the rate and factors associated with the occurrence of stroke, a major cause of death and disability, in adults with GHD.Patients and methods: Data from 15,188 GHD patients treated with GH replacement therapy (GHRT) enrolled in KIMS were analyzed. Stroke incidence rates were compared to rates from the Oxford Vascular ...

ea0049ep884 | Growth hormone IGF axis - basic | ECE2017

Safety of growth hormone replacement therapy (GHRT) in adult patients with GH deficiency: data from kims

Camacho-Hubner Cecilia , Jonsson Peter , Aydin Ferah , Rajicic Natasa , Cara Jose , Abs Roger , Hey-Hadavi Judith

Background: The efficacy of recombinant human growth hormone replacement therapy (GHRT) has been demonstrated, in part, through clinical trials conducted worldwide. KIMS (Pfizer International Metabolic Database), established in 1994 and active until 2012, includes treatment outcome data and real world safety from 15 809 patients from 31 countries.Objective: The main objective of this analysis was to evaluate the long-term safety of patients with hypopitu...

ea0063gp58 | Acromegaly and GH | ECE2019

ACROSTUDY – safety and efficacy in a cohort of 110 Naïve patients with acromegaly treated with pegvisomant

Wajnrajch Michael , Gomez Roy , Hey-Hadavi Judith , Kelepouris Nikoletta , van der Lans Joli , Loftus Jane , Camacho-Hubner Cecilia , Fleseriu Maria , Salvatori Roberto , Cara Jose , Palladino Andrew

Background: ACROSTUDY is an open-label, non-interventional post-authorization safety study that began in 2004 to evaluate safety in at least 1000 acromegaly patients treated with the GH receptor antagonist pegvisomant (PEGV). This commitment was fulfilled in Jan 2013. ACROSTUDY was later amended to enroll an additional 110 patients that were naïve/semi-naive to PEGV treatment. Semi-naïve patients are defined as not having received PEGV therapy for at least 6 months p...